Stockscreener 앱 받기
4.76
1.42%
0.17
전일 마감가:
$4.59
열려 있는:
$4.61
하루 거래량:
3,272
Relative Volume:
0.02
시가총액:
$267.09M
수익:
$30.91M
순이익/손실:
$-74.28M
주가수익비율:
-3.9071
EPS:
-1.2183
순현금흐름:
$-86.15M
1주 성능:
-4.61%
1개월 성능:
-5.00%
6개월 성능:
+8.51%
1년 성능:
+34.93%
1일 변동 폭
$4.55
$4.61
1주일 범위
$4.525
$5.20
52주 변동 폭
$3.26
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
명칭
Foghorn Therapeutics Inc
전화
617-586-3100
주소
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.55 | 269.43M | 30.91M | -74.28M | -86.15M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
434.83 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.33 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.68 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.36 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.52 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 재개 | Jefferies | Buy |
| 2025-12-18 | 개시 | BTIG Research | Buy |
| 2025-11-07 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 재개 | B. Riley Securities | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 개시 | B. Riley Securities | Buy |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-08-19 | 개시 | Evercore ISI | Outperform |
| 2023-03-28 | 개시 | BofA Securities | Buy |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-22 | 개시 | H.C. Wainwright | Buy |
| 2020-11-17 | 개시 | Cowen | Outperform |
| 2020-11-17 | 개시 | Goldman | Buy |
| 2020-11-17 | 개시 | Morgan Stanley | Overweight |
| 2020-11-17 | 개시 | Wedbush | Outperform |
모두보기
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
If You Invested $1,000 in Foghorn Therapeutics Inc. (FHTX) - Stock Titan
Trading Recap: Can Foghorn Therapeutics Inc weather a recession2026 Spike Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Investing News Network
Foghorn to present preclinical cancer data at AACR meeting By Investing.com - Investing.com South Africa
Foghorn Therapeutics details preclinical advances across oncology programs - Traders Union
Foghorn to present preclinical cancer data at AACR meeting - Investing.com
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor ... - Bluefield Daily Telegraph
New lung, breast and blood cancer data put Foghorn programs at AACR - Stock Titan
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
FHTX PE Ratio & Valuation, Is FHTX Overvalued - Intellectia AI
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
FHTX Technical Analysis & Stock Price Forecast - Intellectia AI
FHTX Stock Price, Quote & Chart | FOGHORN THERAPEUTICS INC (NASDAQ:FHTX) - ChartMill
Strength Observed in Dianthus Therapeutics, Inc. (DNTH): Will Its 5.6% Increase Lead to Further Gains? - Bitget
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo! Finance Canada
FHTX Should I Buy - Intellectia AI
Aug Final Week: Can Foghorn Therapeutics Inc weather a recessionCPI Data & High Conviction Investment Ideas - baoquankhu1.vn
Setup Watch: Is Foghorn Therapeutics Inc part of any major index2026 Price Action Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Fundamentals Check: Is Foghorn Therapeutics Inc stock a good dividend stock2026 Earnings Impact & Daily Profit Focused Stock Screening - baoquankhu1.vn
Ideas Watch: Is Foghorn Therapeutics Inc stock a hidden gem2026 Fundamental Recap & Safe Entry Point Identification - baoquankhu1.vn
Citizens reiterates Foghorn Therapeutics stock rating on pipeline progress By Investing.com - Investing.com Canada
What is HC Wainwright's Forecast for FHTX FY2026 Earnings? - MarketBeat
Foghorn Therapeutics’ (FHTX) Outperform Rating Reiterated at Wedbush - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
FY2030 Earnings Estimate for FHTX Issued By HC Wainwright - Defense World
Brokers Offer Predictions for FHTX FY2030 Earnings - MarketBeat
Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Foghorn Therapeutics (FHTX) FY 2025 Losses Reinforce Bearish Unprofitability Narrative - simplywall.st
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data By Investing.com - Investing.com Australia
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data - Investing.com India
Foghorn Therapeutics reports $158.9M cash position, extends runway - Investing.com Australia
Foghorn Therapeutics (NASDAQ:FHTX) Earns "Outperform" Rating from Wedbush - MarketBeat
Stifel reiterates Foghorn Therapeutics stock rating at buy By Investing.com - Investing.com Australia
Stifel reiterates Foghorn Therapeutics stock rating at buy - Investing.com
Foghorn Therapeutics: Pioneering Precision Oncology with Chromatin Regulatory System Targeting and Gene Traffic Control Platform - Minichart
Foghorn Advances FHD-909 Trial and Strengthens Financial Position - TipRanks
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook - Bitget
Foghorn Therapeutics Inc. (FHTX) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Foghorn Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Foghorn Therapeutics 10-K: $30.9M revenue, $(1.18) EPS - TradingView
Foghorn Therapeutics (NASDAQ:FHTX) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Foghorn Therapeutics (FHTX) maps chromatin-targeting cancer pipeline with Lilly - Stock Titan
Foghorn Therapeutics (NASDAQ: FHTX) narrows 2025 loss and extends cash runway into 2028 - Stock Titan
Cancer drug developer Foghorn raises $50M, funds work on hard-to-treat tumors - Stock Titan
Foghorn Therapeutics Inc (FHTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.65%
자본화:
|
볼륨(24시간):